Medivolve Announces Webinar to Discuss Telehealth Strategy
Medivolve will host a webinar Monday, February 22nd at 1 pm ET with medical advisor Dr. Glenn Copeland to discuss Collection Sites telehealth strategy. Further, Tim Shelburn is stepping down from his executive role at Collection Sites.
Toronto, Ontario, February 16, 2021 — Medivolve Inc. (“Medivolve” or the “Company”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce it is hosting a Corporate Update webinar, Monday, February 22nd at 1 pm ET that will provide investors with an update on the Company's recent business developments and telehealth strategy.
Registration Link: https://us02web.zoom.us/webinar/register/WN_Nw7_20QGRqyn5BHMWlYZnQ
Specifically, the webinar will feature Medivolve CEO Doug Sommerville and Dr. Glenn Copeland to discuss Collection Sites telehealth strategy. Dr. Glenn Copeland is a medical advisor to Medivolve and CEO of Glenco Medical, a Medivolve partner company. With Dr. Copeland’s guidance, Medivolve and Collection Sites are developing telehealth plans that include remote patient monitoring and virtual care, among other offerings. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.
Medivolve is also announcing that Tim Shelburn, President of Collection Sites, its wholly-owned subsidiary will be stepping down from all executive roles within Collection Sites. Tim will remain as an arms-length advisor while Collection Sites transitions to new leadership. Tim Shelburn held no executive role at Medivolve.
“Mr. Shelburn’s work for Collection Sites was integral to establishing the company. Today, Collection Sites continues to help keep Americans working by providing quick and convenient access to important testing services across the Country and is a key component of Medivolve,” said Doug Sommerville, CEO of Medivolve. “We are in the process of transitioning to new leadership at Collection Sites and would like to thank Mr. Shelburn for his contributions to date.”
About Medivolve, Inc.
Medivolve, Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.
Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.
Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.